Literature DB >> 6254163

[Clinical study of the action of a new molecule, veralipride, on menopausal psychofunctional disorders (author's transl)].

L Delanian.   

Abstract

A preliminary open study was conducted in 20 women with menopausal sudden flushes to assess the effect of veralipride, administered as 100 mg/day for 20 days. In 15 cases, sudden flushes and night sweats were no longer present following treatment and behaviour had considerably improved. In the remaining 5 cases, sudden flushes were reduced in number and severity. A second study was then conducted in 40 women with the same symptoms, to compare the efficacy of veralipride and placebo under double-blind conditions. Successful results were obtained in 15 patients after veralipride and 5 after placebo, while treatment was a failure in 5 patients after veralipride and 15 after placebo. The difference is very significant in favor of veralipride (p < 0,01). Best results were obtained on sudden flushes, followed by mood and behavior disorders, with less consistent results in headache, pruritus vulvae, and palpitations. Clinical tolerance was good as only 4 cases of difficulty in falling asleep, 3 cases of mammary tension, and 2 cases of dryness of the mouth were reported. Biological parameters and vaginal smears were not modified by treatment.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6254163

Source DB:  PubMed          Journal:  Sem Hop


  1 in total

Review 1.  [Prevention of secondary manifestations of menopause. Perspectives and alternatives].

Authors:  H J Welti
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.